T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell therapy for patients with solid tumors. Its approach combines internally-developed T cell enhancements to create supercharged T cells designed to achieve deeper responses and durability. The proprietary MyT platform is a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.